BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 12034106)

  • 1. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children.
    Sepúlveda-Amor J; Valdespino-Gómez JL; García-García Mde L; Bennett J; Islas-Romero R; Echaniz-Aviles G; de Castro JF
    Vaccine; 2002 Jun; 20(21-22):2790-5. PubMed ID: 12034106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren.
    Bennett JV; Fernandez de Castro J; Valdespino-Gomez JL; Garcia-Garcia Mde L; Islas-Romero R; Echaniz-Aviles G; Jimenez-Corona A; Sepulveda-Amor J
    Bull World Health Organ; 2002; 80(10):806-12. PubMed ID: 12471401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
    Crovari P; Gabutti G; Giammanco G; Dentico P; Moiraghi AR; Ponzio F; Soncini R
    Vaccine; 2000 Jun; 18(25):2796-803. PubMed ID: 10812221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
    Usonis V; Bakasenas V; Kaufhold A; Chitour K; Clemens R
    Pediatr Infect Dis J; 1999 Jan; 18(1):42-8. PubMed ID: 9951979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of measles and rubella vaccines in Oman: a prospective clinical trial.
    Kohler KA; Suleiman AJ; Robertson SE; Malankar P; Al-Khusaiby S; Helfand RF; Brown D; Bellini WJ; Sutter RW
    J Infect Dis; 2003 May; 187 Suppl 1():S177-85. PubMed ID: 12721911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children.
    Wong-Chew RM; Islas-Romero R; García-García Mde L; Beeler JA; Audet S; Santos-Preciado JI; Gans H; Lew-Yasukawa L; Maldonado YA; Arvin AM; Valdespino-Gómez JL
    Vaccine; 2006 Jan; 24(5):683-90. PubMed ID: 16154241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial.
    Dilraj A; Cutts FT; de Castro JF; Wheeler JG; Brown D; Roth C; Coovadia HM; Bennett JV
    Lancet; 2000 Mar; 355(9206):798-803. PubMed ID: 10711928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
    Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
    Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous and intranasal administration of RA 27-3 rubella vaccine. Alone and in conjunction with live attenuated measles vaccine.
    Saidi S; Naficy K
    Am J Dis Child; 1969 Aug; 118(2):209-12. PubMed ID: 5794816
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
    Watson BM; Laufer DS; Kuter BJ; Staehle B; White CJ; Starr SE
    J Infect Dis; 1996 Mar; 173(3):731-4. PubMed ID: 8627041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A; Gerike E
    Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The clinico-immunological evaluation of a bivalent vaccine against measles and rubella].
    Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
    Minerva Pediatr; 1990 Dec; 42(12):531-6. PubMed ID: 2087226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and reactogenicity of indigenously produced MMR vaccine.
    Bhargava I; Chhaparwal BC; Phadke MA; Irani SF; Chhaparwal D; Dhorje S; Maheshwari CP
    Indian Pediatr; 1995 Sep; 32(9):983-8. PubMed ID: 8935261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
    Dennehy PH; Saracen CL; Peter G
    Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus.
    Christenson B; Böttiger M
    Vaccine; 1994 Feb; 12(2):129-33. PubMed ID: 8147093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes.
    Coté TR; Sivertson D; Horan JM; Lindegren ML; Dwyer DM
    Public Health Rep; 1993; 108(4):431-5. PubMed ID: 8341775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial of a new trivalent measles-mumps-rubella vaccine in young children.
    Vesikari T; Ala-Laurila EL; Heikkinen A; Terho A; D'Hondt E; André FE
    Am J Dis Child; 1984 Sep; 138(9):843-7. PubMed ID: 6383020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection.
    Cilla G; Peña B; Marimón JM; Pérez-Trallero E
    Vaccine; 1996 Apr; 14(6):492-4. PubMed ID: 8782345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.